Bard Financial Services Inc. Buys 12,500 Shares of GSK PLC Sponsored ADR $GSK

Key Points

• Bard Financial Services Inc. increased its stake in GSK PLC by 10.2%, now owning 134,745 shares valued at approximately $5.17 million.
• GSK's recent quarterly earnings showed an EPS of $1.23, surpassing estimates, and a revenue of $10.64 billion, indicative of a 1.3% year-over-year growth.
• The company has announced a quarterly dividend of $0.4206, which translates to an annualized dividend yield of 4.1%.

Bard Financial Services Inc. boosted its stake in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 10.2% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 134,745 shares of the pharmaceutical company's stock after purchasing an additional 12,500 shares during the period. Bard Financial Services Inc.'s holdings in GSK were worth $5,174,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in GSK. Dodge & Cox boosted its holdings in shares of GSK by 14.9% in the first quarter. Dodge & Cox now owns 78,651,833 shares of the pharmaceutical company's stock worth $3,046,972,000 after buying an additional 10,210,921 shares during the last quarter. Primecap Management Co. CA raised its position in GSK by 1.8% in the first quarter. Primecap Management Co. CA now owns 25,708,020 shares of the pharmaceutical company's stock worth $995,929,000 after acquiring an additional 446,360 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in shares of GSK by 2.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 7,722,314 shares of the pharmaceutical company's stock worth $299,163,000 after acquiring an additional 155,392 shares during the last quarter. Royal Bank of Canada grew its position in shares of GSK by 5.7% during the 1st quarter. Royal Bank of Canada now owns 7,581,079 shares of the pharmaceutical company's stock valued at $293,692,000 after acquiring an additional 411,869 shares during the period. Finally, Equity Investment Corp increased its stake in shares of GSK by 5.3% in the 1st quarter. Equity Investment Corp now owns 4,174,189 shares of the pharmaceutical company's stock worth $161,708,000 after purchasing an additional 211,608 shares in the last quarter. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

GSK Price Performance

Shares of GSK stock opened at $40.81 on Monday. The stock has a market cap of $83.12 billion, a price-to-earnings ratio of 18.89, a price-to-earnings-growth ratio of 2.04 and a beta of 0.53. The company has a debt-to-equity ratio of 1.07, a quick ratio of 0.57 and a current ratio of 0.87. The stock has a 50 day moving average price of $38.74 and a 200-day moving average price of $38.47. GSK PLC Sponsored ADR has a one year low of $31.72 and a one year high of $43.62.

GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 EPS for the quarter, beating the consensus estimate of $1.12 by $0.11. The company had revenue of $10.64 billion for the quarter, compared to the consensus estimate of $7.92 billion. GSK had a net margin of 10.81% and a return on equity of 49.22%. The firm's revenue was up 1.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.43 EPS. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. Equities analysts expect that GSK PLC Sponsored ADR will post 4.14 EPS for the current year.

GSK Cuts Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 9th. Stockholders of record on Friday, August 15th will be issued a $0.4206 dividend. The ex-dividend date is Friday, August 15th. This represents a $1.68 annualized dividend and a dividend yield of 4.1%. GSK's payout ratio is currently 77.78%.

Analysts Set New Price Targets

Several equities analysts recently weighed in on GSK shares. Berenberg Bank reiterated a "hold" rating on shares of GSK in a research report on Tuesday, June 3rd. Wall Street Zen upgraded GSK from a "buy" rating to a "strong-buy" rating in a research note on Friday, September 5th. Six equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, GSK presently has a consensus rating of "Reduce" and an average target price of $37.38.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.